This page contains promotional content
Welcome to the Roche Ireland resource for Esbriet. Please find links below to support your patients being treated with Esbriet, including patient booklets and other medical resources.
Esbriet is available for Advanced IPF.
The ESBRIET EU Idiopathic Pulmonary Fibrosis (IPF) indication includes patients with ADVANCED IPF:
Esbriet is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF).
This license is based on the clinical trial MA29957 (1) and also post-hoc analyses of pivotal IPF trials (CAPACITY [2] & ASCEND [3]).
This item needs to be read along with the Safety Checklist for Prescribing Physician Esbriet® (pirfenidone) - Risk Minimisation Materials.
abc
Patient Booklet
To download digital copies or order physical copies of Patient Booklets for Esbriet.
Further Information
Please report adverse events to:
The Drug Surveillance Centre
Roche Products (Ireland) limited
3004, Lake Drive, Citywest, Naas Road, Dublin 24
Tel: +353 (0)1 469 0700
Email: ireland.drug_surveillance_centre@roche.com
Alternatively, suspected adverse reactions should be reported to:
HPRA Pharmacovigilance
Website: hpra.ie
